FDA approves Sun Pharma's Ilumya for psoriatic arthritis
The US FDA approved Sun Pharma's Ilumya for adults with active psoriatic arthritis on 30 October 2026; phase 3 response rates were not released.
The US Food and Drug Administration approved Sun Pharma's Ilumya (tildrakizumab-asmn) for adults with active psoriatic arthritis (PsA) on 30 October 2026, according to the company's announcement as reported by Healio, Pharmaceutical Executive and Practical Dermatology. The approval rests on two phase 3 trials, INSPIRE-1 and INSPIRE-2, which together enrolled more than 800 adults. Both trials met their main goal, but the announcement gave no response rates, so the size of the benefit is not yet public. Ilumya was first approved in 2018 for plaque psoriasis.
What the FDA approved
Ilumya is an injectable biologic drug that blocks interleukin-23 (IL-23), a signalling protein involved in inflammation in psoriasis and psoriatic arthritis. PsA is a chronic condition in which the immune system attacks the joints, often in people who already have the skin disease psoriasis. The new approval extends Ilumya from skin disease to joint disease in adults with active PsA.
Per the reports, the dose is 100 mg given as an injection under the skin, in the trial schedule at weeks 0 and 4 and then every 12 weeks, though Pharmaceutical Executive notes the announcement did not describe a broader schedule. Ilumya is administered only by a healthcare provider. Sun Pharma presents that as an advantage for patients who cannot inject themselves or who benefit from regular office visits. The company's North America CEO, Rick Ascroft, said Ilumya is now an option for adults who "are unable to self-administer treatment", as Healio quotes.
The company's own estimate, reported by Pharmaceutical Executive, is that up to 2.4 million Americans have PsA. It says roughly one in three people with psoriasis also have PsA, and more than 15% of people with psoriasis may have undiagnosed PsA. These are company figures.
What the two trials tested
INSPIRE-1 and INSPIRE-2 were global, randomised, double-blind, placebo-controlled phase 3 trials of tildrakizumab 100 mg over 52 weeks, sponsored by Sun Pharma. INSPIRE-1 enrolled patients who had previously taken a TNF inhibitor, another class of arthritis drug. INSPIRE-2 enrolled patients who had not. The primary endpoint was ACR20 at week 24: the share of patients with at least a 20% improvement on the American College of Rheumatology scale, which counts tender and swollen joints and other measures.
Healio and Pharmaceutical Executive report that tildrakizumab was superior to placebo on that endpoint in both trials, and that Sun Pharma said so in 2025. The October announcement did not give response rates, effect sizes, secondary endpoints or results by prior TNF use, and it did not describe how long the benefit lasts beyond week 24. Sun Pharma said full results will be presented at a future medical meeting and published, according to Pharmaceutical Executive.
On safety, Sun Pharma reports no new safety signals and a profile consistent with earlier tildrakizumab studies. Practical Dermatology notes upper respiratory infections and COVID-19 were among the most common adverse reactions, and that patients should be checked for tuberculosis before treatment. Healio reports plaque psoriasis, upper respiratory infections, injection site reactions and diarrhoea each occurred in fewer than 5% of study participants. The two outlets word the safety details differently, so the full label should be consulted.
What earlier studies suggest, and what is missing
The earlier evidence gives context but is not a substitute for the phase 3 numbers. Pharmaceutical Executive reports that in the psoriasis trials reSURFACE 1 and 2, 61% to 66% of patients on the 100 mg or 200 mg dose reached PASI 75 (a 75% improvement in skin scores) at week 12, against 6% on placebo. In the phase 2b PsA trial of 391 patients, 71.4% to 79.5% of those on Ilumya reached ACR20 at week 24, against 50.6% on placebo. The placebo response was higher than expected, and no improvement in dactylitis (swollen fingers or toes) or enthesitis (inflamed tendon attachments) was seen.
That last point matters for patients with those symptoms and is exactly what the phase 3 data should clarify. Until then, what is confirmed is the approval, the two trials meeting their primary endpoint and the lack of new safety signals. What is not confirmed is the size of the benefit in phase 3, how it compares with other IL-23 and IL-17 drugs, and how durable it is. What is unknown includes launch timing, price and how insurers will view a drug given only in an office.
How the drug fits the market
PsA is already treated with several biologics, including TNF inhibitors and drugs that block IL-17 or IL-23. A new IL-23 option matters mainly for patients and doctors who want to avoid self-injection or who like the regular schedule of supervised visits, which is the angle Sun Pharma has chosen. Rheumatologist Philip Mease, lead author of the INSPIRE trials, said an IL-23 inhibitor given by a healthcare provider gives doctors a new way to individualise care, per Healio and Practical Dermatology.
For Sun Pharma, an Indian drugmaker, this is an expansion of a specialty drug that is already approved for plaque psoriasis in India, Australia, Canada, China and Japan, and sold in Europe as Ilumetri by Almirall, as Pharmaceutical Executive reports. A second indication can widen the patient pool in the United States. How much revenue it brings is not stated in any source we reviewed.
What it means for patients and doctors
For people with PsA, the approval adds an option but not yet a clear ranking against existing drugs. Choices depend on which joints and skin areas are affected, prior treatments and other conditions, and need a specialist. Nothing here is medical advice.
A practical point is the in-office administration model. It suits people who struggle with injections, but it means regular visits, with the cost and time that involves. Patients with a history of tuberculosis or active infection need screening first, as the safety information says.
To understand what response rates mean, try the simulator. It uses the phase 2b numbers reported above as defaults, so it shows how absolute and relative differences work, not the performance of the approved drug.
Reading an approval announcement carefully
Company announcements of approvals follow a pattern: they state that a trial "met its primary endpoint" and leave out the numbers until a conference. That is not unusual, and it is not a sign of a problem. It does mean readers should keep three things apart: what the regulator has decided (the approval and the label), what the company says about the trials (met the goal, no new safety signals) and what outside experts can check (nothing yet, because the data are unpublished). A drug can beat placebo and still offer a modest benefit, so the response rates and the comparison with existing treatments are what will decide how widely doctors use it.
What to watch next
The key event is the presentation and publication of the INSPIRE-1 and INSPIRE-2 results at a future medical meeting, which will give ACR20 rates, secondary endpoints and any difference by prior TNF use. Also watch for the US launch timing and pricing, any label detail on dosing, and whether Sun Pharma discusses PsA contribution to Ilumya sales in its next results.
Key takeaways
- The FDA approved Ilumya (tildrakizumab-asmn) for adults with active psoriatic arthritis on 30 October 2026, based on two phase 3 trials with more than 800 adults.
- Both trials met the primary ACR20 endpoint at week 24, but the announcement gave no response rates or effect sizes.
- Sun Pharma reports no new safety signals; patients should be screened for tuberculosis before treatment.
- Ilumya is given only by a healthcare provider, which the company positions as an option for patients who cannot self-inject.
- An earlier phase 2b study showed higher-than-expected placebo response and no improvement in dactylitis or enthesitis, which the phase 3 data should address.
Sources
- [Healio: FDA approves Ilumya for adults with psoriatic arthritis](https://www.healio.com/news/rheumatology/20261030/fda-approves-ilumya-for-adults-with-psoriatic-arthritis)
- [Pharmaceutical Executive: FDA approves Ilumya (tildrakizumab) for active psoriatic arthritis](https://pharmexec.com/view/fda-approves-ilumya-tildrakizumab-active-psoriatic-arthritis)
- [Practical Dermatology: FDA approves tildrakizumab for adults with active psoriatic arthritis](https://practicaldermatology.com/news/fda-approves-tildrakizumab-for-adults-with-active-psoriatic-arthritis/2488879/)
Tags: FDA Drug approval Sun Pharma Psoriatic arthritis Biologics